Edinburgh-based Cell Therapy Contract Development and Manufacturing Organization RoslinCT has been awarded a Research & Development grant from Scottish Enterprise of up to USD 9.59 million to accelerate the digital transformation of its manufacturing operations in Scotland.

The announcement, made on 6 October 2026, forms part of the company's ambitious digital expansion plan, a multi-year initiative designed to enhance the company's integrated digital and AI capabilities and further strengthen Scotland's position as a global hub for advanced cell and gene therapy manufacturing.

Enhancing Digital Manufacturing Capabilities

The funding will enable the development of a digitally integrated manufacturing environment, improving operational efficiency, data connectivity, and manufacturing excellence across RoslinCT's operations.

According to the company, by creating a more connected and data-driven manufacturing environment, RoslinCT will be better positioned to support clients throughout the product lifecycle, helping bring innovative cell therapies to patients faster and more cost-effectively.

Digital Technologies Reshaping Advanced Therapy Manufacturing

The announcement comes at a time when digital technologies are playing an increasingly important role in delivering robust, scalable and efficient manufacturing processes for advanced therapies, as demand for these treatments continues to grow.

RoslinCT's investment will help create a more connected manufacturing ecosystem, supporting the development and manufacture of life-changing cell therapies while creating high-value employment opportunities in Scotland.

The programme forms part of RoslinCT's long-term strategy to invest in advanced manufacturing technologies and create a highly connected, digitally enabled manufacturing environment that supports both clinical and commercial cell therapy production.

The company states that the project is also expected to contribute significantly to Scotland's life sciences sector through job creation and long-term economic growth.

Industry Leadership Voices Support for the Programme

Peter Coleman, Chief Executive Officer of RoslinCT, welcomed the award, describing the support from Scottish Enterprise as an important investment in the future of advanced therapy manufacturing in Scotland. "Digital technologies are transforming how cell therapies are developed and manufactured, enabling greater efficiency, consistency, and scalability while maintaining the highest quality standards," Coleman said.

"At RoslinCT, we are committed to building world-class manufacturing capabilities that help our clients bring innovative therapies to patients faster. This programme will strengthen our digital infrastructure, support continued innovation and reinforce Scotland's position as a leading destination for cell and gene therapy manufacturing."

Scottish Enterprise Chief Executive Adrian Gillespie also highlighted the significance of the award, noting that Scotland's life sciences sector has built a strong international reputation for innovation and expertise. "RoslinCT's ambitious digital programme demonstrates their continued leadership in this field," Gillespie said.

"This R&D project is a prime example of how Scottish Enterprise support can enable innovation at scale and strengthen competitiveness in global markets."

Scottish Government Endorses the Initiative

The award also drew support from the Scottish Government, with Minister for Business & Fair Work Tom Arthur describing the grant as good news for Edinburgh, good news for Scotland's life sciences sector, and good news for the advancement of work that is improving and saving lives across the world.

Arthur noted that over the last twenty years, RoslinCT has established itself as a Scottish success story, delivering and manufacturing life-changing therapies for cancer, genetic disorders, and other complex medical conditions.

"The Scottish Government and our enterprise agencies recognise the importance of helping our life sciences sector remain internationally competitive and will continue supporting and investing in our fantastic, world-renowned innovation," the Minister said.

RoslinCT's Capabilities and Heritage

RoslinCT continues to invest in expanding its capabilities across process development, analytical development, GMP manufacturing, and commercial readiness, helping cell therapy developers accelerate the delivery of innovative treatments to patients worldwide.

The company is a leading global CDMO focused on advanced cell therapies, operating 22 purpose-built cGMP cell therapy suites across two sites: Edinburgh, Scotland, and Hopkinton, Massachusetts.

RoslinCT provides process and analytical development and clinical and commercial manufacturing for both autologous and allogeneic cell therapies, as well as iPSC cell line development, gene editing, and differentiation services.

Founded in 2005 and built on the scientific heritage of the Roslin Institute, home of the groundbreaking cloning of Dolly the Sheep, RoslinCT has played a pivotal role in advancing innovative cell-based medicines from early development through commercialization, with manufacture of commercial products at both of its sites.

The company is a GHO Capital portfolio company.

Scottish Enterprise's Role in the Scottish Economy

Scottish Enterprise, the body behind the grant, is Scotland's national economic development agency and a non-departmental public body of the Scottish Government. The agency supports businesses to innovate and scale to transform the Scottish economy by focusing on new market opportunities through targeted investment, innovation and internationalisation.

A Broader Commitment to Scotland's Life Sciences Future

The USD 9.59 million award underscores the convergence of commercial ambition and public sector support in Scotland's life sciences landscape.

With backing from Scottish Enterprise and endorsement from the Scottish Government, RoslinCT's digital expansion plan is positioned to advance both the company's own manufacturing capabilities and the wider goal of reinforcing Scotland's international standing in cell and gene therapy manufacturing.

As the programme moves forward, the company states it will create a more connected and data-driven manufacturing environment intended to benefit clients throughout the product lifecycle and, ultimately, patients awaiting innovative cell therapies.

Stay Ahead of the United Kingdom's Industrial Expansion with Real-Time Project Intelligence

The United Kingdom's industrial landscape is shifting fast; new manufacturing hubs, energy-efficient retrofit initiatives, and cross-border infrastructure investments are reshaping where the next opportunity will emerge. But without timely, verified project data, even the most established players risk being reactive instead of proactive.

The Global Project Tracking (GPT) platform by Blackridge Research delivers comprehensive, continuously updated intelligence on industrial developments across the United Kingdom, empowering suppliers, contractors, and investors to identify and pursue opportunities before competitors even know they exist.

From early-stage announcements to final commissioning, every milestone matters, and every milestone is tracked.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Book a Free Demo today and discover how the Global Project Tracking (GPT) platform by Blackridge Research can transform your United Kingdom market strategy into a measurable pipeline of wins.